ImmunityBio, Inc.
General ticker "IBRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.9B (TTM average)
ImmunityBio, Inc. follows the US Stock Market performance with the rate: 20.8%.
Estimated limits based on current volatility of 6.1%: low 8.87$, high 10.02$
Factors to consider:
- Total employees count: 680 (+8.3%) as of 2024
- US accounted for 96.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Single product reliance, High R&D costs, Regulatory and compliance, Manufacturing scale up, Intellectual property risks
- Current price 137.6% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.50$, 4.58$]
- 2025-12-31 to 2026-12-31 estimated range: [1.23$, 3.77$]
Financial Metrics affecting the IBRX estimates:
- Positive: with PPE of -3.9 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -20.95 <= 0.01
- Positive: -4.43 < Investing cash flow per share per price, % of -0.66
Short-term IBRX quotes
Long-term IBRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.62MM | $14.74MM | $113.29MM |
| Operating Expenses | $362.87MM | $358.93MM | $369.31MM |
| Operating Income | $-362.25MM | $-344.18MM | $-256.03MM |
| Non-Operating Income | $-221.64MM | $-69.46MM | $-95.58MM |
| Interest Expense | $129.20MM | $154.33MM | $112.53MM |
| R&D Expense | $232.37MM | $190.14MM | $207.88MM |
| Income(Loss) | $-583.89MM | $-413.64MM | $-351.61MM |
| Taxes | $-0.04MM | $0.00MM | $-0.14MM |
| Profit(Loss)* | $-583.20MM | $-413.56MM | $-351.40MM |
| Stockholders Equity | $-586.99MM | $-489.10MM | $-499.57MM |
| Inventory | $0.00MM | $8.27MM | $0.91MM |
| Assets | $504.45MM | $382.93MM | $501.90MM |
| Operating Cash Flow | $-366.76MM | $-391.24MM | $-304.94MM |
| Capital expenditure | $30.58MM | $6.89MM | $0.00MM |
| Investing Cash Flow | $-30.47MM | $-12.25MM | $-149.80MM |
| Financing Cash Flow | $558.34MM | $281.63MM | $400.24MM |
| Earnings Per Share** | $-1.15 | $-0.59 | $-0.38 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.